Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686959 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT00686959: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00686959 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 598 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00686959, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Primary Outcome
Overall survival (OS) time is from baseline to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Etoposide
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
What the finished NCT00686959 record still lists
NCT00686959 is an interventional study that assigns participants to a tested intervention. The registered 598 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00686959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00686959 about?
NCT00686959 is a clinical study titled "Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer". This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
What is the current status of trial NCT00686959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2008-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00686959?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Etoposide (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT00686959?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00686959's enrollment target sits among peer trials
598 640th of 2000 higher than 1,361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia